Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Dolutegravir Intermediate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN106754806B discloses a high-efficiency transaminase for synthesizing (R)-3-aminobutanol, offering superior substrate tolerance and eliminating organic cosolvents for cost-effective manufacturing.
Novel patent CN106966912B enables efficient Dolutegravir intermediate production with high optical purity and scalable manufacturing processes for global supply chains.
Patent CN110668958A reveals a high-purity synthesis route for (R)-3-aminobutanol, a key Dolutegravir intermediate, offering significant cost and supply chain advantages.
Advanced low-temperature synthesis of 4-methoxy ethyl acetoacetate via patent CN107311861A. Delivers high-purity pharmaceutical intermediates with optimized supply chain reliability.
Patent CN108752217B reveals a green, low-cost route for 2,4-difluorobenzylamine, a key dolutegravir intermediate, offering significant supply chain advantages.
Patent CN110358804B reveals high-purity enzymatic resolution for dolutegravir synthesis, offering scalable biocatalysis solutions for reliable pharmaceutical intermediate suppliers.
Patent CN115594600A reveals a safer, one-step synthesis of chiral (R)-3-aminobutanol using borohydride, offering significant cost reduction and supply chain reliability for API manufacturers.